Shaping death: how the microbiome regulates tumour cell demise and therapy response

Martina Raudenska1,2, Jan Balvan1,2, Eliska Zgarbova1,2,3

  • 1Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.

Cancer Metastasis Reviews
|February 19, 2026
PubMed

Insights

Cancer cell death pathways are modulated by the gut microbiome, impacting cancer malignancy and therapy resistance. Understanding this interplay offers new strategies for microbiome-informed cancer treatments.

Area of Science:

  • Oncology
  • Microbiology
  • Cell Biology

Background:

  • Cell death is crucial for tissue homeostasis and the tumor microenvironment.
  • Cancer cells often evade cell death, contributing to malignancy and treatment resistance.
  • Non-malignant cell death can cause adverse effects during cancer therapy.

Purpose of the Study:

  • To review the intersection of cell death and the microbiome in cancer.
  • To summarize how microbes and metabolites influence cancer cell death pathways.
  • To explore how this crosstalk impacts anticancer therapy response.

Main Methods:

  • Literature review integrating knowledge on cell death and microbiome interactions.
  • Focus on key metabolic mediators influencing cell fate decisions.
  • Analysis of the bidirectional relationship between cell death and microbial ecosystems.

Main Results:

  • The tumor and gut microbiomes critically modulate cancer cell death processes.
  • Cell death influences microbial ecosystems by altering nutrient availability and immune signaling.
  • Microbial metabolites play a role in cancer cell fate decisions.

Conclusions:

  • The interplay between cell death and the microbiome is underexplored but critical in cancer.
  • Understanding this bidirectional crosstalk opens avenues for precision microbiome-informed cancer therapies.
  • Targeting the tumor-microbiome axis can help "preserve the good and eliminate the bad" in cancer treatment.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K